In the News
July 08, 2014
Interview with Rebecca M. Shanahan, CEO of Avella Specialty Pharmacy, a speaker at IIR's upcoming Annual Summit for Oncology Management, July 21-23, in Philadelphia.
June 29, 2014
Rebecca Shanahan spends a lot of her time dealing with orphans. Not people: drugs. "Orphan drugs are those needed by a small population of patients, usually 6,000 or fewer," says Shanahan, CEO of Avella Specialty Pharmacy. "The challenge for drug manufacturers is that they have to put all of the effort into research, development and testing. Often times, the cost of getting the drug from its inception to market requires a disproportionate expense as compared to what the return on the investment would be."
May 23, 2014
Donna M. Smith, Pharm.D., director of clinical affairs at Avella Specialty Pharmacy discusses developments in the treatment of lung cancer that specialty pharmacies need to be aware of. This video was shot at the Armada Health Care 2014 Specialty Pharmacy Summit and Expo in Las Vegas, Nevada.
May 20, 2014
Emerging therapies and the role of specialty pharmacies in the treatment of non-small cell lung cancer were discussed during a continuing education session at the annual Armada summit.
May 12, 2014
CEO of Avella Specialty Pharmacy Rebecca M. Shanahan, Esq., discusses how specialty pharmacies can best manage the rising cost of specialty drugs to improve outcomes for patients. This video was shot at the Armada Health Care 2014 Specialty Pharmacy Summit and Expo in Las Vegas, Nevada.
May 01, 2014
Patient care, communication and coordination take center stage as Diplomat Specialty Pharmacy, Avella Specialty Pharmacy, Amber Pharmacy and 32 other select companies begin distributing apremilast, the first FDA-approved oral therapy for psoriatic arthritis.
March 19, 2014
Avella Specialty Pharmacy on Tuesday announced that it has registered with the Food and Drug Administration as an outsourcing facility for sterile compounding as outlined in the recently enacted Drug Quality and Security Act. Outsource facilities must consent to greater federal oversight including more frequent inspections and are required to demonstrate their adherence to specific “good manufacturing practices,” Avella noted.
February 24, 2014
Health care providers have long recognized nonadherence as a major barrier to positive patient health outcomes and a significant cause of increased health care costs. Nonadherence dates back to Hippocrates, who advised physicians “to keep watch for that fault in patients which makes them lie about the things prescribed.” Robert Koch, the 1905 Nobel Prize winner for his discovery of the bacterium that causes tuberculosis, described noncompliant patients as “vicious consumptives, careless and/or irresponsible.” Perhaps the most succinct and straightforward description of nonadherence is then-Surgeon General of the United States Dr. C. Everett Koop’s famous quote of the 1980s, “Drugs don’t work in patients who don’t take them.”
February 21, 2014
As part of a study conducted with the University of Arizona, Avella Specialty Pharmacy proved the value of pharmacist intervention in improving patient outcomes, at least in renal transplant patients, to the tune of $27,852 per month, Avella announced Thursday. The study found that participants in the intervention group had a statistically significant improvement in adherence rates over patients in the control group who did not have a contract or receive support to ensure adherence to their monthly medication therapy. The study also found that patients who complied with their medication regimens had fewer inpatient and outpatient visits and were 78% more likely not to be hospitalized, hence the monthly savings.
February 20, 2014
Accountable care organizations (ACOs)—the trending new delivery model in which care is coordinated to achieve both cost efficiencies and improved quality—offer a rich new field of possible partnership opportunities for specialty pharmacy, suggested experts participating in the first of a series of webinars on ACOs and specialty pharmacy cosponsored by Avalere Health, Armada Health Care and the Specialty Pharmacy Association of America (SPAARx).
From the Avella Blog
July 30, 2014
Healthcare is rapidly adopting new technologies that can help patients better manage their health, improve their adherence and make more informed choices about their care. Specialty pharmacies play a critical role in these efforts. Avella, in partnership with Novartis Pharmaceuticals Corporation, offers our patients GlowCap®, an easy-to-use, wireless technology tool that uses lights, sounds and interactive reminders to notify patients to take their medication. This unique adherence tool guides ...